Breaking News, Collaborations & Alliances

NMT Pharma and CAO Pharma Form Pact

Will further develop and market anti-cancer drug CZ-48

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Singapore-based NMT Pharmaceuticals Pte Ltd. has formed an agreement with U.S.-based CAO Pharmacueticals Inc. for acquiring an exclusive worldwide license right to further develop and market an anti-cancer drug CZ-48 co-developed by CAO Pharma and NMT Pharma. NMT Pharma and CAO Pharma will enter into agreements that would secure funding needed by CAO Pharma to continue to operate and conduct clinical trials in the U.S. The collaboration is subjected to, among other requirements, satisfactory ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters